Assay for detection of human parvovirus B19 nucleic acid

1. A reaction mixture containing a combination of at least two separate nucleic acid oligomers, wherein the first oligomer is selected from the group consisting of:

a) SEQ ID NO:6,

b) the complete complement of SEQ ID NO:6, and

c) the RNA equivalent of the sequence of a) or b),

wherein the first oligomer optionally includes a promoter sequence joined to the 5′ terminus of the sequence;

and wherein the second oligomer is selected from the group consisting of:

d) SEQ ID NO:13,

e) the complete complement of SEQ ID NO:13, and

f) the RNA equivalent of the sequence of d) or e).

2. The combination of oligomers of claim 1 wherein the oligomer that consists of SEQ ID NO:6 and a promoter sequence joined to the 5′ terminus of SEQ ID NO:6 consists of SEQ ID NO:5.

3. The combination of oligomers of claim 1 wherein the promoter sequence joined to the 5′ terminus of the sequence is the promoter sequence of SEQ ID NO:19.

4. The combination of oligomers of claim 1 , further comprising a third nucleic acid oligomer that contains a target complementary sequence of 27 to 33 nucleotides and which includes a target specific sequence consisting of a) SEQ ID NO:41, b) the complete complement of SEQ ID NO:41, or c) the RNA equivalent of the sequence of a) or b); and optionally a 3′ tail portion that is nonspecific for a parvovirus target sequence, and wherein the target specific sequence optionally includes at least one 2′-methoxy substituted RNA group.

5. The combination of oligomers of claim 4 wherein the third oligomer contains the target specific sequence consisting of a) SEQ ID NO:20, b) the complete complement of SEQ ID NO:20, or c) the RNA equivalent of the sequence of a) or b); and optionally a 3′ tail portion that is nonspecific for a parvovirus target.

6. The combination of oligomers of claim 4 wherein the third oligomer contains the target specific sequence consisting of a) SEQ ID NO:21, b) the complete complement of SEQ ID NO:21, or c) the RNA equivalent of the sequence of a) or b); and optionally a 3′ tail portion that is nonspecific for a parvovirus target.

7. The combination of oligomers of claim 4 , wherein the target specific sequence of the third oligomer includes at least one 2′-methoxy substituted RNA group.

8. The combination of oligomers of claim 1 , further comprising a third nucleic acid oligomer consisting of a target specific sequence of at least 25 contiguous bases contained in a) SEQ ID NO:1, b) the complete complement of SEQ ID NO:1, or c) the RNA equivalent of the sequence of a) or b); and optionally a 3′ tail portion that is nonspecific for a parvovirus target.

9. The combination of oligomers of claim 1 , further comprising a third nucleic acid oligomer with a sequence consisting of a) SEQ ID NO:36, b) the complete complement of SEQ ID NO:36, or c) the RNA equivalent of the sequence of any a) or b).

10. The combination of oligomers of claim 9 wherein the third oligomer includes at least one 2′-methoxy substituted RNA group.

11. A method of detecting human parvovirus B19 nucleic acid in a biological sample, comprising the steps of:

amplifying in vitro a portion of a parvovirus B19 nucleic acid contained in a biological sample by using at least one nucleic acid polymerase activity and at least one first amplification oligomer and one second amplification oligomer, selected from the group consisting of

a first amplification oligomer consisting of SEQ ID NO:5 or SEQ ID NO:6 optionally including a promoter sequence joined to a 5′ terminus of SEQ ID NO:6, and

a second amplification oligomer consisting of SEQ ID NO:13; and

detecting an amplified product of the parvovirus B19 nucleic acid by using a labeled detection probe comprising: a nucleic acid sequence consisting of SEQ ID NO:17 with an acridinium ester compound (“AE”) linked between positions 7/8 or 11/12, a nucleic acid sequence consisting of SEQ ID NO:27 with an AE linked between positions 7/8 or 9/10 or 12/13 or 13/14, a nucleic acid sequence consisting of SEQ ID NO:28 with an AE linked between positions 12/13, a nucleic acid sequence consisting of SEQ ID NO:30 with an AE linked between positions 5/6 or 13/14, a nucleic acid sequence consisting of SEQ ID NO:31 with an AE linked between positions 9/10 or 10/11, a nucleic acid sequence consisting of SEQ ID NO:32 with an AE linked between positions 8/9 or 12/13, a nucleic acid sequence consisting of SEQ ID NO:34 with an AE linked between positions 7/8 or 9/10 or 11/12 or 13/14 or 16/17 or 17/18, a nucleic acid sequence consisting of SEQ ID NO:36 with an AE linked between positions 6/7 or 7/8 or 10/11 or 11/12 or 14/15 or 15/16, and a nucleic acid sequence consisting of SEQ ID NO:37 with an AE linked between positions 7/8 or 8/9 or 9/10 or 11/12 or 12/13 or 14/15 or 16/17 or 17/18 or 18/19, thereby indicating presence of parvovirus B19 nucleic acid in the biological sample.

12. The method of claim 11 wherein the amplifying step uses the oligomer consisting of the sequence of SEQ ID NO:6 including a promoter sequence joined to the 5′ terminus of SEQ ID NO:6, wherein the promoter sequence is a T7 promoter sequence.

13. The method of claim 12 wherein the amplifying step uses the oligomer consisting of the sequence of SEQ ID NO:6 including a promoter sequence joined to the 5′ terminus of SEQ ID NO:6, wherein the T7 promoter sequence is the sequence of SEQ ID NO:19.

14. The method of claim 11 , further comprising a step of separating the parvovirus B19 nucleic acid from the sample before the amplifying step by using a nucleic acid oligomer selected from the group consisting of:

a target complementary sequence of 27 to 33 nucleotides that contains the target specific sequence consisting of a) SEQ ID NO:41, b) the complete complement of SEQ ID NO:41, or c) the RNA equivalent of the sequence of a) or b); and optionally a 3′ tail sequence that is nonspecific for a parvovirus sequence;

the target specific sequence consisting of d) SEQ ID NO:20, e) the complete complement of SEQ ID NO:20, or f) the RNA equivalent of the sequence of d) or e); and optionally a 3′ tail sequence that is nonspecific for a parvovirus sequence;

the target specific sequence consisting of g) SEQ ID NO:21, h) the complete complement of SEQ ID NO:21, or i) the RNA equivalent of the sequence of g) or h); and optionally a 3′ tail portion that is nonspecific for a parvovirus sequence; and

a target complementary sequence of at least 25 contiguous bases contained in j) SEQ ID NO:1, k) the complete complement of SEQ ID NO:1, or l) the RNA equivalent of the sequence of j) or k); and optionally a 3′ tail sequence that is nonspecific for a parvovirus sequence.

15. The method of claim 11 wherein the amplifying step uses an amplification reaction that is substantially isothermal.

16. The method of claim 11 , wherein the detecting step uses a labeled detection probe comprising at least one 2′-methoxy substituted RNA group.